March 2025 Life Sciences Update

Germany: Rhine-Neckar Region

MARKETS CONTENTS

Market Summary

Public & Private Funding (2024)

Fast Lab Stats

• The investment market showed signs of stabilization in 2024, with stable prime yields in the top seven markets. B cities, such as Mainz and Heidelberg, have experienced a further increase in yields, along with greater liquidity for high quality investment product. A stronger dynamic on the commercial real estate market is expected in 2025. • The Rhine-Neckar region, particularly Mainz and Heidelberg, has experienced a significant rise in interest from public institutions seeking to strengthen their presence in the life sciences sector. Existing life sciences campuses plan to expand over the next 10-15 years and are set to receive public funding for this growth. The region is emerging as an interregional cluster, with several strong life sciences campuses. • The region boasts a prestigious university landscape, including university hospitals in Heidelberg and Mannheim, as well as several key institutions, such as the German Cancer Research Centre, the European Molecular Biology Laboratory and the Max Planck Institute. • Health + Life Sciences Alliance Heidelberg Mannheim, an innovative network of university institutions and research centers, has been established to strengthen the sector within the economic region and to expand it into a leading international cluster in the life sciences. • There are 12 life sciences companies employing more than 10,000 people in Mainz, Heidelberg, Mannheim and Ludwigshafen.

€ Raised (MM)

Company

Deal Type

Completed

Type

150K Total Life Sciences Employment > 64 Life Science Companies > 10 Research facilities/ institutes

Qualifyze

Later Stage VC

Sep 2024

5th Round

€ 54.0

NeraCare

Later Stage VC

May 2024

1st Round

€ 20.0

FundaMental Pharma

Seed Round

Apr 2024

1st Round

€ 10.0

Heidelberg Epignostix

Seed Round

Jul 2024

1st Round

€ 4.3

LigniLabs

Grant

May 2024

€ 0.27

FaCellitate

Accelerator/Incubator

Apr 2024

Pixel Biosciences

Later Stage VC

Aug 2024

3rd Round

Umlaut (Biotechnology)

Early Stage VC

Jul 2024

1st Round

Representative Investment Sale Transactions (2023 – 2024)

Address

Type

Volume (€m)

GLA (sqm)

Date Buyer

Honeycamp Building, Mannheim R&D / Office

Confidential

11,500 2022 Q4 BNP Paribas REIM

Representative Life Sciences Companies

Life Sciences Labor: Annual Chemist Job Postings

Company

Type

450

Representative Lease Transactions (2023 – 2024)

400

Company

Address

GLA (sqm)

New/Renewal

Type

Quarter

Landlord

Cellzome

Biotechnology

350

300

Ascendis Pharma

Grüne Meile, Heidelberg

11,650 New letting

Office/labs

Q3 2022

Max-Jarecki-Stiftung

BD Becton Dickinson

Medtech

250

AbbVie Pharmaceutics Knollstraße 50

8,000 Owner Occupier

Office

Q1 2024

AbbVie Pharmaceutics

200

Anwerina Deutschland

Pharma

150

100

Reckit Beckister

Chemicals

50

-

Roche Diagnostics

Pharma

2019

2020

2021

2022

Bio Degree-Awarding Institutions, Metro Area

Heidelberg University

•

• Ruprecht-Karls-Universität Heidelberg • Johannes Gutenberg-Universität Mainz • Hochschule Mannheim • Karlsruhe Institute of Technology (KIT)

Contributors Benedikt Kiefer benedikt.kiefer@cushwake.com

Simon Jeschioro simon.jeschioro@cushwake.com

Sources: Cushman & Wakefield Research, CoStar, National Institutes of Health (NIH), Lightcast, Pitchbook, Federal Reserve Economic Data (FRED)

Cushman & Wakefield

86